Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline

Company Overview - Akebia Therapeutics (NASDAQ: AKBA) is focused on developing treatments for kidney-related diseases, primarily utilizing its HIF platform [1]. Transition and Risks - The company is currently transitioning from its existing product Auryxia to a new product, Vafseo, which presents a significant risk for the company [1]. - Despite the risks associated with this transition, Vafseo is reportedly experiencing some early successes in the market [1].